AstraZeneca Plc (AZN)

36.10
NYSE : Health Technology
Prev Close 36.10
Day Low/High 0.00 / 0.00
52 Wk Low/High 28.43 / 37.30
Avg Volume 3.87M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 90.85B
EPS 1.20
P/E Ratio 16.33
Div & Yield 1.37 (3.76%)

Latest News

Stocks Mixed After Trump-Kim Summit, Wall Street Looks to Fed Meeting

Stocks Mixed After Trump-Kim Summit, Wall Street Looks to Fed Meeting

Stocks finished mixed on Tuesday, following the summit between Donald Trump and North Korean leader Kim Jong Un and as Wall Street turns its attention the start of the Federal Reserve's two-day meeting.

Jim's Daily Rundown

Jim discusses our Salesforce buy, Eli Lilly, UnitedHealth and Cimarex and also answers a club member's question!

Peace Hopes Weigh on Defense Stocks

Shares of defense stocks slide after Trump meets Kim.

Trump Meets Kim, AT&T and Time Warner, McDonald's - 5 Things You Must Know

Trump Meets Kim, AT&T and Time Warner, McDonald's - 5 Things You Must Know

U.S. stock futures trade lower after a signed agreement between Donald Trump and North Korean leader Kim Jong Un offers few specifics on denuclearization of the Korean peninsula; a ruling on the AT&T and Time Warner merger is expected Tuesday; McDonald's reportedly to detail its restructuring plan.

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

I continue to see these names as bargains in the biotech and biopharma space.

Seroquel Stepping Stone: How Luye Will Use Seroquel To Expand In Emerging Markets

Seroquel Stepping Stone: How Luye Will Use Seroquel To Expand In Emerging Markets

SHANGHAI, June 6, 2018 /PRNewswire/ -- The $538 million acquisition by Luye Pharma Group Ltd.

Small Cap Biotech Bargains

Small Cap Biotech Bargains

Here are 2 small caps I continue to see as bargains in this space.

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics shares got destroyed on Monday. Here is why.

Moxetumomab Pasudotox Pivotal Data In Patients With Previously-Treated Hairy Cell Leukemia Presented At The 2018 ASCO Meeting

Moxetumomab Pasudotox Pivotal Data In Patients With Previously-Treated Hairy Cell Leukemia Presented At The 2018 ASCO Meeting

AstraZeneca and MedImmune, its global biologics research and development arm, today presented results from the Phase III ('1053') clinical trial (Abstract #7004) that evaluated moxetumomab pasudotox in 80 patients with relapsed or refractory hairy cell...

IMFINZI® (Durvalumab) Significantly Improves Overall Survival In The Phase III Pacific Trial For Unresectable Stage III Non-Small Cell Lung Cancer

IMFINZI® (Durvalumab) Significantly Improves Overall Survival In The Phase III Pacific Trial For Unresectable Stage III Non-Small Cell Lung Cancer

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive overall survival (OS) results for the Phase III PACIFIC trial, a randomized, double-blinded, placebo-controlled, multi-center trial of IMFINZI ®...

AstraZeneca Heads To 2018 ASCO Annual Meeting With Its Diversified Oncology Portfolio And Next-Generation Pipeline

AstraZeneca Heads To 2018 ASCO Annual Meeting With Its Diversified Oncology Portfolio And Next-Generation Pipeline

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, June 1-5, 2018, with an expanded portfolio in Oncology.

LOKELMATM Approved In The US For The Treatment Of Adults With Hyperkalemia

LOKELMATM Approved In The US For The Treatment Of Adults With Hyperkalemia

AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved LOKELMA TM (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of hyperkalemia in adults.

LOKELMATM Approved In The US For The Treatment Of Adults With Hyperkalemia

LOKELMATM Approved In The US For The Treatment Of Adults With Hyperkalemia

AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved LOKELMA TM (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of hyperkalemia in adults.

4 Great Dividend Stocks That Always Remember to Say 'Thank You': Market Recon

4 Great Dividend Stocks That Always Remember to Say 'Thank You': Market Recon

These dividend payers compete in businesses that I'm interested in and believe in -- and they pay me to own the shares.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

US FDA Approves BYDUREON For Use With Basal Insulin In Patients With Type 2 Diabetes With Inadequate Glycemic Control

US FDA Approves BYDUREON For Use With Basal Insulin In Patients With Type 2 Diabetes With Inadequate Glycemic Control

AstraZeneca today announced the US Food and Drug Administration (FDA) has approved BYDUREON ® (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes...

US FDA Accepts Biologics License Application For Moxetumomab Pasudotox In Hairy Cell Leukemia

US FDA Accepts Biologics License Application For Moxetumomab Pasudotox In Hairy Cell Leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an...

AstraZeneca Presents New Data Evaluating Safety And Efficacy Of FARXIGA In Patients With Type 2 Diabetes And Moderate Renal Impairment

AstraZeneca Presents New Data Evaluating Safety And Efficacy Of FARXIGA In Patients With Type 2 Diabetes And Moderate Renal Impairment

AstraZeneca today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA ® (dapagliflozin 10 mg), in patients with type 2 diabetes (T2D) with moderate renal impairment...

AstraZeneca Announces Renewed Recommendation And Availability Of FLUMIST QUADRIVALENT Vaccine In The US

AstraZeneca Announces Renewed Recommendation And Availability Of FLUMIST QUADRIVALENT Vaccine In The US

AstraZeneca today announced that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has voted in favor of a renewed recommendation for the use of FLUMIST ®...

Ionis Licences New Antisense Drug For Kidney Disease To AstraZeneca

Ionis Licences New Antisense Drug For Kidney Disease To AstraZeneca

Ionis earns $30 million license fee

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

LYNPARZA® (olaparib) Approved By US FDA In Germline BRCA-Mutated Metastatic Breast Cancer

LYNPARZA® (olaparib) Approved By US FDA In Germline BRCA-Mutated Metastatic Breast Cancer

AstraZeneca and Merck (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA ® (olaparib), for use in patients with deleterious or...

US FDA Accepts Regulatory Submission For TAGRISSO (Osimertinib) In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

US FDA Accepts Regulatory Submission For TAGRISSO (Osimertinib) In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for the use of TAGRISSO ® (osimertinib), a third-generation, irreversible epidermal...

AstraZeneca's CALQUENCE® (acalabrutinib) Shows Potential In Chronic Lymphocytic Leukemia Trials

AstraZeneca's CALQUENCE® (acalabrutinib) Shows Potential In Chronic Lymphocytic Leukemia Trials

AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II...

TheStreet Quant Rating: B (Buy)